Polyplus-transfection Unveils Technology to Improve Intracellular Delivery of Small Interfering RNAs In-vivo
News Apr 25, 2008
Polyplus-transfection has announced the development of a new technology that improves in vivo delivery of small interfering RNAs (siRNAs) when they are associated with a cationic polymer. This technology is based on a new class of small interfering RNAs the company has developed: "sticky siRNAs" (ssiRNAs).
The technology involves extending the opposite ends of interfering RNAs with complementary sequences. SsiRNAs stick together end-to-end in the presence of a cationic polymer such as in vivo-jetPEI (also developed by Polyplus-transfection) and thus form complexes as stable as with genes.
With this new technology, small interfering RNAs stay connected to their delivery reagent during the whole journey to the target cells, and induce the RNA interference mechanism. This innovation is applicable to therapeutic siRNAs, and a wide variety of pathologies could benefit from it such as cancers, allergies and viral diseases.
Up to now, the market for the delivery of therapeutic siRNAs has been dominated by the use of cationic lipids. Thanks to this ssiRNA technology, cationic polymers such as in vivo-jetPEI have now entered the market with clear advantages in specific areas.
"We are proud of having developed this new technology, for which we have filed a broad patent application and have registered the trademark," said the C.E.O. of Polyplus-transfection," Joelle Bloch. "Within a few months, we have succeeded in offering our customers two major therapeutic advances: a GMP-compliant delivery reagent, in vivo-jetPEI, and a new means of delivering siRNAs associated with this reagent. Our customers have already shown a keen interest in these two developments, and ssiRNAs are starting to be tested in vivo by several academic laboratories and biotechnology companies."
Polyplus-transfection's new technology was outlined in an article published in Proceedings of the National Academy of Sciences of the United States of America in October 2007 under the title "Sticky overhangs enhance siRNA-mediated gene silencing", volume 104, pages 16,050-16,055, Bolcato-Bellemin et al.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.